Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical technology company focused on musculoskeletal healthcare, including joint replacement, trauma, spine, and surgical solutions. Shares recently traded around $90 per share, giving the company a market capitalization of roughly $17.8B.
Zimmer Biomet operates in a procedure-driven end market tied closely to aging demographics and elective surgery volumes. Looking at who owns Zimmer Biomet and recent insider trades helps show how large institutions and company leadership appear to be positioning around the stock today.
Who Are Zimmer Biomet’s Top Shareholders?
Zimmer Biomet’s shareholder base is led by large institutional investors. These firms tend to hold through market cycles, which can help keep long-term ownership relatively stable. At the same time, changes among active managers offer insight into where conviction may be strengthening or softening.
- Dodge & Cox: 23,216,173 shares (11.71%), ~$2.09B value. Added 1,118,710 shares (+5.06%).
- The Vanguard Group: 23,192,852 shares (11.70%), ~$2.09B value. Added 31,594 shares (+0.14%).
- T. Rowe Price Associates: 14,777,255 shares (7.46%), ~$1.33B value. Added 276,248 shares (+1.91%).
- BlackRock Institutional Trust: 11,058,321 shares (5.58%), ~$996M value. Added 123,344 shares (+1.13%).
- State Street Investment Management: 8,631,760 shares (4.36%), ~$777M value. Cut 116,486 shares (-1.33%).
- Capital International Investors: 7,550,754 shares (3.81%), ~$680M value. Added 778,467 shares (+11.49%).
- Geode Capital Management: 5,197,223 shares (2.62%), ~$468M value. Added 72,447 shares (+1.41%).
- American Century Investment Management: 5,176,696 shares (2.61%), ~$466M value. Cut 532,674 shares (-9.33%).
- Harris Associates: 4,750,567 shares (2.40%), ~$428M value. Added 1,018,466 shares (+27.29%).
- PRIMECAP Management: 4,250,630 shares (2.14%), ~$383M value. Cut 460,200 shares (-9.77%).
For investors, the mix of meaningful additions and selective trimming suggests differing views on valuation rather than a broad shift in sentiment toward Zimmer Biomet.
Hedge Fund Highlights
Schonfeld Strategic Advisors, founded by Steven Schonfeld, sharply increased its Zimmer Biomet position by 3,633.7%, now holding roughly $45.7M value in the stock. The scale of the increase stands out relative to its prior exposure.
Millennium Management, led by founder Israel Englander, boosted its stake by 1,031.8%, lifting its position to about $13.5M value, which may reflect a more constructive tactical view.
Harris Associates, founded by Irving Harris and led by Bill Nygren, raised its position by 27.3% to approximately $468M value, reinforcing its role as one of Zimmer Biomet’s more conviction-driven long-term holders.
Ariel Investments, founded by John Rogers, increased its stake by 55.9% to roughly $38.9M value, consistent with its value-oriented investment style.
For investors, hedge fund activity points to selective confidence rather than consensus, with some managers leaning in while others remain measured.
Track the top shareholders of over 50,000 global stocks (It’s free) >>>
Zimmer Biomet’s Recent Insider Trades
Recent filings show mostly small transactions that lean toward selling and equity-related activity.
- Lori Winkler (Officer/Director): Sold 123 shares at ~$97.52; recorded additional shares at $0.
- Suketu P. Upadhyay (Officer): Sold 4,731 shares at ~$87.73; recorded 10,632 shares at $0.
- Sang Yi (Officer): Sold 1,200 shares at ~$103.59.
- Multiple Directors: Small sales and $0 share recordings ranging from ~140 to ~382 shares.
These transactions do not materially shift insider ownership levels. It appears like many filings may be tied to compensation timing or personal portfolio management, though that cannot be confirmed. For investors, insider activity currently offers context rather than a strong directional signal.
See recent insider trade data for over 50,000 global stocks (It’s free) >>>
What the Ownership & Insider Trade Data Tell Us
Zimmer Biomet’s ownership remains anchored by long-term institutions such as Dodge & Cox, Vanguard, and T. Rowe Price, providing a stable shareholder base. Among active managers, recent position changes reflect a range of views rather than a unified stance.
Insider activity appears modest in size and impact, with no large purchases or exits. For investors, the data suggests Zimmer Biomet continues to be treated as a steady, institutionally supported medical technology company, with ownership trends reflecting measured confidence at current price levels.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
